Abstract

Cell-based therapies using mesenchymal stem cells (MSCs) are a promising tool in bone tissue engineering. Bone regeneration with MSCs involves a series of molecular processes leading to the activation of the osteoinductive cascade supported by bioactive factors, including fibroblast growth factor-2 (FGF-2) and bone morphogenetic protein-2 (BMP-2). In this study, we examined the biological characteristics and osteogenic differentiation potential of sheep bone marrow MSCs (BM-MSCs) treated with 20 ng/mL of FGF-2 and 100 ng/mL BMP-2 in vitro. The biological properties of osteogenic-induced BM-MSCs were investigated by assessing their morphology, proliferation, phenotype, and cytokine secretory profile. The osteogenic differentiation was characterized by Alizarin Red S staining, immunofluorescent staining of osteocalcin and collagen type I, and expression levels of genetic markers of osteogenesis. The results demonstrated that BM-MSCs treated with FGF-2 and BMP-2 maintained their primary MSC properties and improved their osteogenic differentiation capacity, as confirmed by increased expression of osteocalcin and collagen type I and upregulation of osteogenic-related gene markers BMP-2, Runx2, osterix, collagen type I, osteocalcin, and osteopontin. Furthermore, sheep BM-MSCs produced a variety of bioactive factors involved in osteogenesis, and supplementation of the culture medium with FGF-2 and BMP-2 affected the secretome profile of the cells. The results suggest that sheep osteogenic-induced BM-MSCs may be used as a cellular therapy to study bone repair in the preclinical large animal model.

Highlights

  • Large bone defects and delayed fracture unions and non-unions, if not repaired effectively by the body, result in pain and lead to morbidity and prolonged, expensive hospitalization [1]

  • The ovine bone marrow-derived mesenchymal stem cells altered their morphology when cultured for 21 days in: (1) complete αMEM, (2) αMEM supplemented with fibroblast growth factor-2 (FGF-2), (3) αMEM supplemented with FGF-2 and bone morphogenetic protein-2 (BMP-2), (4) osteogenic differentiation medium, (5) osteogenic differentiation medium

  • Our results suggest that treatment with FGF-2 and BMP-2 significantly improves the osteogenic potential of ovine BM-mesenchymal stem cells (MSCs) on both the molecular and the protein level

Read more

Summary

Introduction

Large bone defects and delayed fracture unions and non-unions, if not repaired effectively by the body, result in pain and lead to morbidity and prolonged, expensive hospitalization [1]. Bone disorders, such as osteoarthritis and osteoporosis, and the aging of the population constitute serious issues and challenging clinical problems. Orthopedic surgery has made great advances, the gold standard for bone defect repair is still dominated by autologous or allogeneic bone grafts. There are limitations related to bone allografts, such as donor site complications, inferior healing compared to autologous grafts, and risk of disease and infective agent transmission [3]

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call